Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tamatinib |
| Synonyms | |
| Therapy Description |
Tamatinib (R406) inhibits SYK, resulting in decreased downstream signaling and and potentially leading to reduced tumor cell proliferation and viability (PMID: 16946104, PMID: 26251761, PMID: 30668583). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tamatinib | R406|R-406 | SYK Inhibitor 15 | Tamatinib (R406) inhibits SYK, resulting in decreased downstream signaling and and potentially leading to reduced tumor cell proliferation and viability (PMID: 16946104, PMID: 26251761, PMID: 30668583). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 Q575del | hematologic cancer | sensitive | Tamatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tamatinib (R406) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). | 33914060 |
| FLT3 I836D FLT3 I836L | hematologic cancer | no benefit | Tamatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tamatinib (R406) did not inhibit viability of transformed cells expressing FLT3 I836D and I836L in culture (PMID: 28077790). | 28077790 |
| FLT3 I836S | hematologic cancer | no benefit | Tamatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tamatinib (R406) did not inhibit viability of transformed cells expressing FLT3 I836S in culture (PMID: 28077790). | 28077790 |
| FLT3 D835K FLT3 D835L | hematologic cancer | no benefit | Tamatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tamatinib (R406) did not inhibit viability of transformed cells expressing FLT3 D835L and D835K in culture (PMID: 28077790). | 28077790 |
| FLT3 D835A | hematologic cancer | no benefit | Tamatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tamatinib (R406) did not inhibit viability of transformed cells expressing FLT3 D835A in culture (PMID: 28077790). | 28077790 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|